T. Rowe Price Associates’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $255M | Buy |
687,400
+202,326
| +42% | +$60.5M | 0.03% | 445 |
|
|
2026
Q1 | $125M | Sell |
485,074
-44,881
| -8% | -$11.9M | 0.01% | 569 |
|
|
2025
Q4 | $131M | Buy |
529,955
+62,897
| +13% | +$13.2M | 0.01% | 571 |
|
|
2025
Q3 | $82.5M | Buy |
467,058
+205,675
| +79% | +$30.8M | 0.01% | 667 |
|
|
2025
Q2 | $35.9M | Sell |
261,383
-149,478
| -36% | -$22M | ﹤0.01% | 819 |
|
|
2025
Q1 | $74.1M | Sell |
410,861
-98,598
| -19% | -$16.6M | 0.01% | 612 |
|
|
2024
Q4 | $79.8M | Buy |
509,459
+71,200
| +16% | +$12.6M | 0.01% | 624 |
|
|
2024
Q3 | $79.8M | Sell |
438,259
-161,886
| -27% | -$31.2M | 0.01% | 619 |
|
|
2024
Q2 | $110M | Sell |
600,145
-58,473
| -9% | -$9.82M | 0.01% | 528 |
|
|
2024
Q1 | $117M | Buy |
658,618
+231,255
| +54% | +$32.1M | 0.01% | 513 |
|
|
2023
Q4 | $53M | Buy |
427,363
+171,157
| +67% | +$19M | 0.01% | 695 |
|
|
2023
Q3 | $29.7M | Sell |
256,206
-68,741
| -21% | -$8.39M | ﹤0.01% | 824 |
|
|
2023
Q2 | $38.1M | Buy |
324,947
+314,337
| +2,963% | +$32.1M | 0.01% | 775 |
|
|
2023
Q1 | $850K | Buy |
10,610
+688
| +7% | +$54.1K | ﹤0.01% | 1862 |
|
|
2022
Q4 | $786K | Sell |
9,922
-272
| -3% | -$20.2K | ﹤0.01% | 1903 |
|
|
2022
Q3 | $711K | Buy |
10,194
+3,218
| +46% | +$232K | ﹤0.01% | 1945 |
|
|
2022
Q2 | $458K | Sell |
6,976
-2,497
| -26% | -$155K | ﹤0.01% | 2254 |
|
|
2022
Q1 | $630K | Buy |
9,473
+1,368
| +17% | +$85.4K | ﹤0.01% | 2239 |
|
|
2021
Q4 | $567K | Buy |
8,105
+3,886
| +92% | +$226K | ﹤0.01% | 2326 |
|
|
2021
Q3 | $220K | Hold |
4,219
| – | – | ﹤0.01% | 2689 |
|
|
2021
Q2 | $287K | Buy |
4,219
+500
| +13% | +$34.9K | ﹤0.01% | 2610 |
|
|
2021
Q1 | $287K | Buy |
+3,719
| New | +$270K | ﹤0.01% | 2582 |
|
|
2020
Q4 | – | Sell |
-482,899
| Closed | -$20.8M | – | 2703 |
|
|
2020
Q3 | $20.8M | Sell |
482,899
-539,516
| -53% | -$23.4M | ﹤0.01% | 1148 |
|
|
2020
Q2 | $42.3M | Buy |
1,022,415
+129,591
| +15% | +$6.23M | 0.01% | 904 |
|
|
2020
Q1 | $38.6M | Sell |
892,824
-157,761
| -15% | -$8.25M | 0.01% | 867 |
|
|
2019
Q4 | $58.2M | Sell |
1,050,585
-25,173
| -2% | -$1.23M | 0.01% | 864 |
|
|
2019
Q3 | $37.4M | Buy |
1,075,758
+148,679
| +16% | +$6.65M | 0.01% | 966 |
|
|
2019
Q2 | $37.3M | Buy |
927,079
+622,959
| +205% | +$20.4M | 0.01% | 984 |
|
|
2019
Q1 | $10M | Buy |
304,120
+600
| +0.2% | +$14.1K | ﹤0.01% | 1321 |
|
|
2018
Q4 | $6.31M | Buy |
+303,520
| New | +$6.35M | ﹤0.01% | 1380 |
|
Other funds holding KRYS
ACA
SCM
HRCM
T. Rowe Price Associates's KRYS Position: Q2 2026 in Review
T. Rowe Price Associates increased its Krystal Biotech (KRYS) stake by 42% in Q2 2026, buying an estimated $60.5M and bringing the position to 687,400 shares worth $255M. The position accounts for 0.03% of the portfolio, ranked #445.
T. Rowe Price Associates first reported a position in KRYS in Q4 2018 and has held it in 30 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- T. Rowe Price Associates held 687,400 shares of Krystal Biotech worth $255M as of Q2 2026.
- T. Rowe Price Associates bought 202,326 Krystal Biotech shares in Q2 2026, an estimated $60.5M.
- Krystal Biotech made up 0.03% of T. Rowe Price Associates's portfolio in Q2 2026, its #445 holding.
- T. Rowe Price Associates first reported a position in Krystal Biotech in Q4 2018 and has held it in 30 quarters since.
- 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.